These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1022 related items for PubMed ID: 25357015

  • 21. Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
    Williams EA, Montesion M, Shah N, Sharaf R, Pavlick DC, Sokol ES, Alexander B, Venstrom J, Elvin JA, Ross JS, Williams KJ, Tse JY, Mochel MC.
    Mod Pathol; 2020 Dec; 33(12):2397-2406. PubMed ID: 32483240
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.
    Bezić J, Tomić I, Pavić M.
    Acta Dermatovenerol Croat; 2024 Mar; 32(1):75-76. PubMed ID: 38946192
    [Abstract] [Full Text] [Related]

  • 24. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.
    Gutiérrez-Castañeda LD, Gamboa M, Nova JA, Pulido L, Tovar-Parra JD.
    Biomed Res Int; 2020 Mar; 2020():2046947. PubMed ID: 32775409
    [Abstract] [Full Text] [Related]

  • 25. Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.
    Chraybi M, Abd Alsamad I, Copie-Bergman C, Baia M, André J, Dumaz N, Ortonne N.
    Hum Pathol; 2013 Sep; 44(9):1902-11. PubMed ID: 23664541
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
    Mar VJ, Wong SQ, Li J, Scolyer RA, McLean C, Papenfuss AT, Tothill RW, Kakavand H, Mann GJ, Thompson JF, Behren A, Cebon JS, Wolfe R, Kelly JW, Dobrovic A, McArthur GA.
    Clin Cancer Res; 2013 Sep 01; 19(17):4589-98. PubMed ID: 23833303
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J, Knobbe CB, Sterzinger AA, Blaschke B, Schulte KW, Ruzicka T, Reifenberger G.
    Int J Cancer; 2004 Apr 10; 109(3):377-84. PubMed ID: 14961576
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
    Lokhandwala PM, Tseng LH, Rodriguez E, Zheng G, Pallavajjalla A, Gocke CD, Eshleman JR, Lin MT.
    BMC Cancer; 2019 Jul 05; 19(1):665. PubMed ID: 31277584
    [Abstract] [Full Text] [Related]

  • 34. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M, Bajah A, Podewski T, Kreuzberg N, von Bartenwerffer W, Wardelmann E, Merkelbach-Bruse S, Büttner R, Mauch C, Kurschat P.
    Br J Dermatol; 2013 Apr 05; 168(4):708-16. PubMed ID: 23528057
    [Abstract] [Full Text] [Related]

  • 35. KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.
    Zebary A, Jangard M, Omholt K, Ragnarsson-Olding B, Hansson J.
    Br J Cancer; 2013 Aug 06; 109(3):559-64. PubMed ID: 23860532
    [Abstract] [Full Text] [Related]

  • 36. SF3B1, NRAS, KIT, and BRAF Mutation; CD117 and cMYC Expression; and Tumoral Pigmentation in Sinonasal Melanomas: An Analysis With Newly Found Molecular Alterations and Some Population-Based Molecular Differences.
    Wroblewska JP, Mull J, Wu CL, Fujimoto M, Ogawa T, Marszalek A, Hoang MP.
    Am J Surg Pathol; 2019 Feb 06; 43(2):168-177. PubMed ID: 30273197
    [Abstract] [Full Text] [Related]

  • 37. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
    Min KW, Choe JY, Kwon MJ, Lee HK, Kang HS, Nam ES, Cho SJ, Park HR, Min SK, Seo J, Kim YJ, Kim NY, Kim HY.
    Pathol Res Pract; 2019 Dec 06; 215(12):152671. PubMed ID: 31630873
    [Abstract] [Full Text] [Related]

  • 38. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S, Leone DA, Biswas A, Deng A, Jukic D, Singh R, Sundram U, Mahalingam M.
    Hum Pathol; 2018 Dec 06; 82():206-214. PubMed ID: 30120967
    [Abstract] [Full Text] [Related]

  • 39. Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review.
    Gutiérrez-Castañeda LD, Nova JA, Tovar-Parra JD.
    Melanoma Res; 2020 Feb 06; 30(1):62-70. PubMed ID: 31274706
    [Abstract] [Full Text] [Related]

  • 40. Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.
    Knol AC, Pandolfino MC, Vallée A, Nguyen F, Lella V, Khammari A, Denis M, Puaux AL, Dréno B.
    Exp Dermatol; 2015 Jan 06; 24(1):70-3. PubMed ID: 25363723
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 52.